Wendy Dixon

Wendy L.
Dixon is currently Independent Director at Alkermes, Inc. since 2011, Director at Special Equestrians, Inc., and President of Great Meadow Consulting LLC since 2009.
Former roles include Chairman at Sesen Bio, Inc. from 2016 to 2020; Director at DENTSPLY International, Inc. from 2005 to 2010; Independent Director at Incyte Corp.
from 2011 to 2022; Independent Director at Orexigen Therapeutics, Inc. from 2010 to 2016; Independent Director at Furiex Pharmaceuticals, Inc. from 2012 to 2014; Independent Director at Arvinas, Inc. from 2020 to 2024; Independent Director at bluebird bio, Inc. from 2013 to 2021; Independent Director at Ardea Biosciences, Inc. from 2011 to 2012; Director at Edimer Pharmaceuticals, Inc.; Independent Director at Iovance Biotherapeutics, Inc. from 2022 to 2023; Independent Director at Voyager Therapeutics, Inc. from 2017 to 2021; Independent Director at Black Diamond Therapeutics, Inc. from 2022 to 2024; Independent Director at Alkermes Plc from 2011 to 2022; Independent Director at Zevra Therapeutics, Inc. from 2023 to 2025; President & Chief Marketing Officer at Bristol Myers Squibb Co. from 2001 to 2009; Principal at Centocor, Inc.; Senior Vice President-Marketing at Merck & Co., Inc. from 1996 to 2001; Principal at Osteotech, Inc.; Principal at West Pharmaceutical Services, Inc.; Senior Advisor at The Monitor Group, Inc.; and Principal at Smithkline & French Laboratories US, Inc. Education includes undergraduate, graduate, and doctorate degrees from the University of Cambridge.